Coherus Biosciences | CHRS - Current Liabilities


Coherus Biosciences reported $140.39M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Akebia Therapeutics USD 162.94M 29.56M Dec/2025
ALKERMES USD 543.44M 69.08M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 182.23M 3.71M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Baxter International USD 2.97B 805M Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Fujifilm JPY 1.2T 44.21B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Myriad Genetics USD 148M 51.9M Sep/2025
Pacira USD 120.59M 13.51M Dec/2025
Perrigo USD 1.01B 132.4M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xencor USD 95.91M 9.42M Dec/2025
Zoetis USD 2.24B 428M Dec/2025